Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz Acquires 7,491 Shares

Septerna, Inc. (NASDAQ:SEPN) Director Alan Ezekowitz bought 7,491 shares of the firm’s stock in a transaction on Tuesday, March 4th. The shares were bought at an average cost of $6.35 per share, with a total value of $47,567.85. Following the transaction, the director now directly owns 24,911 shares of the company’s stock, valued at approximately $158,184.85. This trade represents a 43.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Alan Ezekowitz also recently made the following trade(s):

• On Thursday, March 6th, Alan Ezekowitz acquired 41,355 shares of Septerna stock. The stock was acquired at an average cost of $6.00 per share, with a total value of $248,130.00.

Septerna Price Performance

Shares of SEPN stock opened at $6.43 on Friday. Septerna, Inc. has a one year low of $4.17 and a one year high of $28.99. The business has a fifty day moving average price of $14.47.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of SEPN. RA Capital Management L.P. bought a new position in Septerna in the fourth quarter worth $160,205,000. TRV GP V LLC bought a new position in Septerna in the fourth quarter worth $142,337,000. TRV GP VI LLC bought a new position in Septerna in the fourth quarter worth $72,191,000. Samsara BioCapital LLC acquired a new position in Septerna during the fourth quarter worth $63,399,000. Finally, Driehaus Capital Management LLC acquired a new position in Septerna during the fourth quarter worth $59,301,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 price objective for the company. TD Cowen assumed coverage on Septerna in a research report on Tuesday, November 19th. They issued a “buy” rating for the company. Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $43.00 to $14.00 in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 price objective on shares of Septerna in a research report on Tuesday, February 11th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.